Showing 2011-2020 of 2192 results for "".
- Ublituximab Treatment Lessened Disability for People With Multiple Sclerosishttps://practicalneurology.com/news/ublituximab-treatment-lessened-disability-for-people-with-multiple-sclerosis/2469565/Treatment of people with relapsing multiple sclerosis (MS) with ublituximab (UTX)(TG Therapeutics; New York, NY) slowed progression of MS as measured with biomarkers and disability progression. Compared with teriflunomide (TFM), ublituximab reduced annualized rate of relapse (ARR), gadolinium enh
- Another Phase 3 Trial of PB-TURSO for Amyotrophic Lateral Sclerosis Being Initiated at FDA Requesthttps://practicalneurology.com/news/another-phase-3-trial-of-pb-turso-for-amyotrophic-lateral-sclerosis-being-initiated-at-fda-request/2469554/A phase 3 trial of sodium phenylbutyrate-taurursodiol (PB-TURSO) (AMX0035; Amylyx Pharmaceuticals, Cambridge, MA) for amyotrophic lateral sclerosis (ALS) is expected to start in the 3rd quarter of 2021. In a nearly 3-year overall survival analysis, those treated with PB-TURSO had a 44% decr
- FDA Gives Marketing Authorization to Translingual Neuromodulation Device for Treatment of Gait Deficits in Multiple Sclerosishttps://practicalneurology.com/news/fda-gives-marketing-authorization-to-translingual-neuromodulation-device-for-treatment-of-gait-deficits-in-multiple-sclerosis/2469546/The Food and Drug Administration (FDA) authorized marketing of a tongue-delivered portable neuromodulation device (PoNS; Helius Medical, Newtown, PA) to treat gait deficit caused by multiple sclerosis (MS). The device is a prescription only adjunct to a supervised therapeutic exercise program for
- Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trialhttps://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatmenthttps://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (
- Prescription Patterns in Multiple Sclerosis Changinghttps://practicalneurology.com/news/prescription-patterns-in-multiple-sclerosis-changing/2469504/Neurologists are prescribing more oral disease-modifying therapy (DMT) for initial treatment of multiple sclerosis (MS) than ever. Out of 1,018 individuals with multiple sclerosis (MS) in a 3-month period, close to half received an oral DMT as their first treatment. Only 4 years ago, the proporti
- Lenalidomide for Potential Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/lenalidomide-for-potential-treatment-of-alzheimer-disease-1/2469487/New phase 2 studies are being initiated for lenalidomide (Revlimid; Bristol Myers Squibb, New York, NY), which is an analogue of thalidomide. Eligible participants include those with early-stage Alzheimer disease (AD)/ mild cognitive impairment (MCI). The first study will evaluate the long-term u
- New Genetic Tests Available for Hereditary Ataxiashttps://practicalneurology.com/news/new-genetic-tests-available-for-hereditary-ataxias/2469486/Several genetic tests, including repeat-expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxia have been newly made available by GeneDx (Gaithersberg, MD). The repeat-expansion analysis may be done concurrently with single nucleotide va
- Clinical Trial of Neuromodulation for Alzheimer Disease and Mild Cognitive Impairment Expandedhttps://practicalneurology.com/news/clinical-trial-of-neuromodulation-for-alzheimer-disease-and-mild-cognitive-impairment-expanded/2469463/Clinical trials of transcranial direct current stimulation (tDCS)(ElectraRx; Soterix Medical, New York, NY) for potential treatment of Alzheimer disease (AD), mild cognitive impairment (MCI), and age-related cognitive decline have been expanded. The study of the proprietary neurostimulation devic